United Therapeutics Surges to Top Trading Volume on Clinical Win and Analyst Hype

Market Snapshot

On March 30, 2026, United Therapeutics (UTHR) surged 12.53%, closing as one of the most actively traded stocks of the day. The company's stock recorded a trading volume of $1.02 billion, marking a 471.71% increase compared to the previous day's volume and ranking as the top trading volume in the market. The stock reached an intraday price of $589.47, nearing its one-year high of $607.89. With a market capitalization of approximately $25.84 billion, UTHR’s performance was driven by strong trading activity and a positive earnings report.

Key Drivers

The sharp rise in UTHR's share price was primarily catalyzed by the clinical success of TETON-1, a late-stage trial for the company’s inhaled treprostinil therapy. The trial met its primary endpoint, demonstrating a statistically significant 130.1 mL improvement in forced vital capacity (FVC) compared to placebo. This result, achieved across 598 patients, is a major milestone in the development of the treatment for idiopathic pulmonary fibrosis (IPF), a condition for which United Therapeutics has long targeted expansion. The trial's success has ignited renewed investor optimism and is widely viewed as a key driver behind the stock's volatility.

Simultaneously, the stock benefited from a series of analyst upgrades and price target increases. TD Cowen raised its target to $660 from $575, UBS Group raised its target to $705 from $655, and HC Wainwright increased its target to $600 from $525—all while maintaining or issuing “buy” ratings. These analyst actions were accompanied by a broader “Moderate Buy” consensus among analysts, with a mean target price of $549.91. The upgraded outlook reflects growing confidence in United Therapeutics’ ability to expand its market share in the IPF space and achieve higher-than-expected revenue growth.

Another contributing factor to the stock's momentum was the unusual volume of call options trading. On March 30, investors executed 16,791 call options, a 789% increase from the typical trading volume of 1,888 call options. This surge in options activity suggests that a significant portion of the market is betting on further upward movement in the stock. With the stock already trading near a one-year high, the increased demand for bullish options positions indicates strong retail and institutional confidence in the company's near-term trajectory.

Despite the positive developments, the stock also faced headwinds in the form of significant insider selling. Over the past 90 days, insiders—including Executive Vice President Paul Mahon and Chief Financial Officer James Edgemond—sold a total of 356,320 shares, valued at approximately $176.8 million. While insiders still maintain a 10.30% ownership stake, the scale of the selling activity has raised questions about potential divergences in insider sentiment. Institutional investors, however, have largely maintained or increased their holdings, with several major funds boosting their stakes by more than 100% in recent quarters. This contrast between insider selling and institutional buying may signal a broader debate among stakeholders about the company's future valuation and growth potential.

Financially, United Therapeutics delivered a strong earnings report on February 25, 2026, posting $7.70 in earnings per share (EPS), which exceeded the consensus estimate of $6.78. The company’s revenue for the quarter stood at $790.20 million, slightly below the expected $814.80 million, but the 7.4% year-over-year growth was a positive sign. The company’s net margin remained robust at 41.94%, and its return on equity (ROE) reached 19.30%. These results, combined with the recent clinical and analyst developments, have led many to believe the company is well-positioned for continued earnings momentum in the current fiscal year.

Taken together, the recent developments—clinical success, analyst upgrades, options activity, and strong earnings—paint a picture of a company in the midst of a significant inflection point. While insider selling has introduced some uncertainty, the broader market appears to be betting on UTHR’s ability to capitalize on its therapeutic advancements and maintain its leadership in pulmonary arterial hypertension and IPF treatment markets.